{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T04:56:25Z","timestamp":1777611385759,"version":"3.51.4"},"reference-count":56,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jcf.2025.12.019","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T04:33:38Z","timestamp":1767069218000},"page":"3-8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Strategies for the identification of people with cystic fibrosis responsive to CFTR modulator triple combinations"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0903-9828","authenticated-orcid":false,"given":"Pierre-R\u00e9gis","family":"Burgel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jcf.2025.12.019_bib0001","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41572-024-00538-6","article-title":"Cystic fibrosis","volume":"10","author":"Mall","year":"2024","journal-title":"Nat Rev Dis Primers"},{"issue":"10408","key":"10.1016\/j.jcf.2025.12.019_bib0002","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/S0140-6736(23)01609-4","article-title":"CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis","volume":"402","author":"Taylor-Cousar","year":"2023","journal-title":"Lancet"},{"issue":"5016","key":"10.1016\/j.jcf.2025.12.019_bib0003","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1126\/science.1712984","article-title":"Demonstration that CFTR is a chloride channel by alteration of its anion selectivity","volume":"253","author":"Anderson","year":"1991","journal-title":"Sci (N Y NY)"},{"issue":"6","key":"10.1016\/j.jcf.2025.12.019_bib0004","doi-asserted-by":"crossref","first-page":"L1117","DOI":"10.1152\/ajplung.00169.2005","article-title":"Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules","volume":"290","author":"Van Goor","year":"2006","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"44","key":"10.1016\/j.jcf.2025.12.019_bib0005","doi-asserted-by":"crossref","first-page":"18825","DOI":"10.1073\/pnas.0904709106","article-title":"Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770","volume":"106","author":"Van Goor","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"issue":"18","key":"10.1016\/j.jcf.2025.12.019_bib0006","doi-asserted-by":"crossref","DOI":"10.1172\/JCI198727","article-title":"Welsh, Gonz\u00e1lez, and Negulescu share Lasker Award recognizing transformative treatments for people with cystic fibrosis","volume":"135","author":"Singer","year":"2025","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcf.2025.12.019_bib0007","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2025.14913","article-title":"Rewriting the chapter on cystic fibrosis: the 2025 Lasker-DeBakey Clinical Medical Research Award","author":"Welsh","year":"2025","journal-title":"Jama"},{"issue":"19","key":"10.1016\/j.jcf.2025.12.019_bib0008","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jcf.2025.12.019_bib0009","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S2213-2600(24)00411-9","article-title":"Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials","volume":"13","author":"Keating","year":"2025","journal-title":"Lancet Respir Med"},{"issue":"10212","key":"10.1016\/j.jcf.2025.12.019_bib0010","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.jcf.2025.12.019_bib0011","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJMoa2100665","article-title":"Triple therapy for cystic fibrosis Phe508del-gating and -residual function genotypes","volume":"385","author":"Barry","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2025.12.019_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2025.10.007","article-title":"Global prevalence of CFTR variants with respect to their responsiveness to elexacaftor-tezacaftor-ivacaftor","author":"Burgel","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2025.12.019_bib0013","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/ppul.25285","article-title":"Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype","volume":"56","author":"McGarry","year":"2021","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"10.1016\/j.jcf.2025.12.019_bib0014","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1186\/s12887-025-06040-6","article-title":"Clinical and genetic characteristics of diseases caused by CFTR gene mutations in 15 Chinese children: a retrospective analysis","volume":"25","author":"Bu","year":"2025","journal-title":"BMC Pediatr"},{"key":"10.1016\/j.jcf.2025.12.019_bib0015","article-title":"CFTR mutations and phenotypic correlations in people with cystic fibrosis: a retrospective study from a single centre in south India","volume":"27","author":"Varkki","year":"2024","journal-title":"Lancet Reg Health Southeast Asia"},{"key":"10.1016\/j.jcf.2025.12.019_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(25)00190-0","article-title":"Sweat chloride and lung function responses to elexacaftor\u2013tezacaftor\u2013ivacaftor in people with cystic fibrosis with two versus one responsive CFTR variants: a an analysis of two real-world observational studies","author":"Burgel","year":"2025","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2025.12.019_bib0017","article-title":"The French Compassionate Program of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del CFTR variant","volume":"61","author":"Burgel","year":"2023","journal-title":"Eur Respir J"},{"issue":"11","key":"10.1016\/j.jcf.2025.12.019_bib0018","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S2213-2600(24)00208-X","article-title":"The expanded French compassionate programme for elexacaftor-tezacaftor-ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study","volume":"12","author":"Burgel","year":"2024","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.jcf.2025.12.019_bib0019","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01959-2023","article-title":"Gathering real-world compassionate data to expand eligibility for elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis with N1303K or other rare CFTR variants: a viewpoint","volume":"63","author":"Burgel","year":"2024","journal-title":"Eur Respir J"},{"issue":"6617","key":"10.1016\/j.jcf.2025.12.019_bib0020","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1126\/science.ade2216","article-title":"Molecular structures reveal synergistic rescue of \u0394508 CFTR by Trikafta modulators","volume":"378","author":"Fiedorczuk","year":"2022","journal-title":"Sci (N Y NY)"},{"issue":"18","key":"10.1016\/j.jcf.2025.12.019_bib0021","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.139983","article-title":"Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination","volume":"5","author":"Veit","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.jcf.2025.12.019_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103476","article-title":"Elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis harbouring two CFTR Class I variants: real-world data from the French compassionate programme","author":"Burgel","year":"2025","journal-title":"eClinicalMedicine"},{"issue":"3","key":"10.1016\/j.jcf.2025.12.019_bib0023","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1091\/mbc.e14-04-0935","article-title":"From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations","volume":"27","author":"Veit","year":"2016","journal-title":"Mol Biol Cell"},{"key":"10.1016\/j.jcf.2025.12.019_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103660","article-title":"Perspectives on the translation of in-vitro studies to precision medicine in Cystic Fibrosis","volume":"73","author":"Dumas","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jcf.2025.12.019_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112989","article-title":"How to determine the mechanism of action of CFTR modulator compounds: a gateway to theranostics","volume":"210","author":"Amaral","year":"2021","journal-title":"Eur J Med Chem"},{"issue":"10","key":"10.1016\/j.jcf.2025.12.019_bib0026","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1164\/rccm.202101-0090LE","article-title":"Elexacaftor\/tezacaftor\/ivacaftor improved clinical outcomes in a patient with N1303K-CFTR based on in vitro experimental evidence","volume":"204","author":"Huang","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"15","key":"10.1016\/j.jcf.2025.12.019_bib0027","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241512365","article-title":"Personalized CFTR modulator therapy for G85E and N1303K homozygous patients with cystic fibrosis","volume":"24","author":"Graeber","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.jcf.2025.12.019_bib0028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1513\/AnnalsATS.201708-668PS","article-title":"The U.S. food and drug administration's experience with ivacaftor in cystic fibrosis. establishing efficacy using in vitro data in lieu of a clinical trial","volume":"15","author":"Durmowicz","year":"2018","journal-title":"Ann Am Thorac Soc"},{"issue":"6","key":"10.1016\/j.jcf.2025.12.019_bib0029","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jcf.2014.09.005","article-title":"Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation","volume":"13","author":"De Boeck","year":"2014","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcf.2025.12.019_bib0030","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/cts.12927","article-title":"G970R-CFTR mutation (c.2908G>C) results predominantly in a splicing defect","volume":"14","author":"Fidler","year":"2021","journal-title":"Clin Transl Sci"},{"issue":"5","key":"10.1016\/j.jcf.2025.12.019_bib0031","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.jcf.2022.04.019","article-title":"Caution advised in the use of CFTR modulator treatment for individuals harboring specific CFTR variants","volume":"21","author":"Raraigh","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.12.019_bib0032","unstructured":"European Medicines Agency. Assessment Report Kaftrio. Available online: https:\/\/wwwemaeuropaeu\/en\/documents\/.assessment-report\/kaftrio-epar-public-assessment-report_en.pdf (accessed on August 13th, 2023)."},{"key":"10.1016\/j.jcf.2025.12.019_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2024.02.006","article-title":"In vitro modulator responsiveness of 655 CFTR variants found in people with cystic fibrosis","author":"Bihler","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.12.019_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(24)00205-4","article-title":"Evaluation of Elexacaftor-Tezacaftor-Ivacaftor treatment in individuals with CF encoding N1303K CFTR: a prospective, multicenter, open-label, single-arm trial","author":"Solomon","year":"2024","journal-title":"Lancet Respir Med"},{"issue":"6","key":"10.1016\/j.jcf.2025.12.019_bib0035","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.jcf.2023.06.001","article-title":"Clinical and functional efficacy of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis carrying the N1303K mutation","volume":"22","author":"Sadras","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2025.12.019_bib0036","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00746-2023","article-title":"Cystic fibrosis airway inflammation enables elexacaftor\/tezacaftor\/ivacaftor-mediated rescue of N1303K CFTR mutation","volume":"10","author":"Gentzsch","year":"2024","journal-title":"ERJ Open Res"},{"issue":"5","key":"10.1016\/j.jcf.2025.12.019_bib0037","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01146-2024","article-title":"Impact of the expanded label for elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis with no F508del variant in the USA","volume":"64","author":"Cromwell","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2025.12.019_bib0038","article-title":"The European Medicines Agency's review of Kaftrio (elexacaftor-tezacaftor-ivacaftor): extending its use to all people with CF aged 2 years and older who do not have two class I CFTR variants","author":"Drai","year":"2025","journal-title":"Eur Respir J"},{"issue":"Suppl 1","key":"10.1016\/j.jcf.2025.12.019_bib0039","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/j.jcf.2022.11.007","article-title":"Patient-derived cell models for personalized medicine approaches in cystic fibrosis","volume":"22","author":"Ramalho","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.jcf.2025.12.019_bib0040","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00110-2023","article-title":"Theratyping cystic fibrosis patients to guide elexacaftor\/tezacaftor\/ivacaftor out-of-label prescription","volume":"62","author":"Dreano","year":"2023","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.jcf.2025.12.019_bib0041","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01855-2024","article-title":"Relationship between theratyping in nasal epithelial cells and clinical outcomes in people with cystic fibrosis","volume":"65","author":"Ratjen","year":"2025","journal-title":"Eur Respir J"},{"issue":"19","key":"10.1016\/j.jcf.2025.12.019_bib0042","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241914539","article-title":"CFTR Function Restoration upon Elexacaftor\/Tezacaftor\/Ivacaftor Treatment in Patient-Derived Intestinal Organoids with Rare CFTR Genotypes","volume":"24","author":"Lefferts","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcf.2025.12.019_bib0043","doi-asserted-by":"crossref","DOI":"10.1007\/s40291-025-00806-5","article-title":"Personalized medicine in cystic fibrosis: characterization of eight rare CFTR variants in intestinal organoids and cellular models","author":"Railean","year":"2025","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.jcf.2025.12.019_bib0044","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/S1569-1993(24)00142-5","article-title":"WS06.03 Efficacy and safety of elexacaftor\/tezacaftor\/ivacaftor (ELX\/TEZ\/IVA) in people with cystic fibrosis and ELX\/TEZ\/IVA-responsive, non-<em>F508del<\/em>genotypes: a phase 3, randomised, placebo-controlled trial","volume":"23","author":"Castellani","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.jcf.2025.12.019_bib0045","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: a clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.jcf.2025.12.019_bib0046","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1164\/rccm.202011-4153OC","article-title":"Rapid improvement after starting elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis and advanced pulmonary disease","volume":"204","author":"Burgel","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2025.12.019_bib0047","doi-asserted-by":"crossref","DOI":"10.1111\/bph.70176","article-title":"In silico, in vitro and ex vivo characterization of cystic fibrosis transmembrane conductance regulator pathogenic variants localized in the fourth intracellular loop and their rescue by modulators","author":"Pesce","year":"2025","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jcf.2025.12.019_bib0048","article-title":"Advances in cystic fibrosis: CFTR modulator triple combinations","author":"Burgel","year":"2025","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.jcf.2025.12.019_bib0049","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: a global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.jcf.2025.12.019_bib0050","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.jcf.2025.06.006","article-title":"Challenges and opportunities of adding CFTR modulators for cystic fibrosis to the WHO essential medicines list","volume":"24","author":"Costa","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2025.12.019_bib0051","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1002\/ppul.26954","article-title":"International disparities in diagnosis and treatment access for cystic fibrosis","volume":"59","author":"Guo","year":"2024","journal-title":"Pediatr Pulmonol"},{"issue":"10","key":"10.1016\/j.jcf.2025.12.019_bib0052","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.71338","article-title":"Cystic fibrosis care in South Africa: facing the challenge of diversity and inequality","volume":"60","author":"Zampoli","year":"2025","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2025.12.019_bib0053","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhlto.2025.100210","article-title":"Evaluation of elexacafor\/tezacaftor\/ivacaftor therapy after lung transplantation in cystic fibrosis: the Dutch National KOALA study","volume":"7","author":"van Gemert","year":"2025","journal-title":"JHLT Open"},{"issue":"10","key":"10.1016\/j.jcf.2025.12.019_bib0054","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1021\/acschembio.3c00310","article-title":"CFTR folding: from structure and proteostasis to cystic fibrosis personalized medicine","volume":"18","author":"McDonald","year":"2023","journal-title":"ACS Chem Biol"},{"issue":"2","key":"10.1016\/j.jcf.2025.12.019_bib0055","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jcf.2021.09.020","article-title":"Functional restoration of <em>CFTR<\/em>nonsense mutations in intestinal organoids","volume":"21","author":"de Poel","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"10","key":"10.1016\/j.jcf.2025.12.019_bib0056","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/S2213-2600(23)00297-7","article-title":"Advancing the pipeline of cystic fibrosis clinical trials: a new roadmap with a global trial network perspective","volume":"11","author":"Mayer-Hamblett","year":"2023","journal-title":"Lancet Respir Med"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325025494?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325025494?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T04:35:31Z","timestamp":1768365331000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199325025494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1569199325025494"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2025.12.019","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Strategies for the identification of people with cystic fibrosis responsive to CFTR modulator triple combinations","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2025.12.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}